Key facts
- This page summarizes Melita Sun Jung's Form 4 filing for Terns Pharmaceuticals, Inc. (TERN).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Feb 2025, 19:28.
Melita Sun Jung - 30 Jan 2025 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)
- Reporting relationship
- Chief Business Officer
- Issuer ticker
- TERN
- Reported as of
- 30 Jan 2025
- Net transaction value
- +$11,498
- SEC form
- 4
- Accepted by SEC
- 03 Feb 2025, 19:28:43 UTC
- Prior SEC filing
- 02 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Strauss, as Attorney-in-Fact for Melita Sun Jung
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Melita Sun Jung filed Form 4 for Terns Pharmaceuticals, Inc. (TERN) on 03 Feb 2025.
Change
- Previous filing in this sequence was filed on 02 May 2024.
- Current net transaction value: +$11,498.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TERN
transaction
Common Stock
Purchase
- Transaction value
- $11,498
- Shares
- +2,250
- Change %
- Price
- $5.11
- Shares after
- 2,250
- Date
- 30 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TERN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +325,000
- Change %
- Price
- $0.000000
- Shares after
- 325,000
- Date
- 30 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 325,000
- Exercise price
- $4.64
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 2,250 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2024.
Footnote F2
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.